Bellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock

On the heels of the FDA lifting its clinical hold on lead product BPX-501, Bellicum announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All shares of common stock to be sold in the offering will be offered by Bellicum.